{"a":[{"_":"‘Seeing the evolution’: As branded patent cliff looms, biosimilar experts size up US hurdles, opportunities ahead","$":{"href":"/pharma/weve-been-seeing-evolution-branded-patent-cliff-looms-biosimilar-experts-size-us-hurdles","hreflang":"en"}}]}

Summary

With over a decade since the first FDA biosimilar approval, biosimilar copies of major biologics including AbbVie's Humira, J&J's Stelara, and Regeneron/Bayer's Eylea are demonstrating strong launches in the US market as a branded patent cliff approaches.